MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain StudyGlobeNewsWire · 2 days ago
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA ReviewGlobeNewsWire · Sep 17, 2026
Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, MexicoNewsfile Corp · Sep 3, 2026
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward INDGlobeNewsWire · Sep 1, 2026
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1GlobeNewsWire · Aug 6, 2026
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling StudiesGlobeNewsWire · Jul 30, 2026MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | – | -$0.03 | |
| May 14, 2026 | – | -$0.03 | |
| Mar 31, 2026 | -$0.04 | -$0.15 | Miss |
| Nov 13, 2025 | -$1.18 | -$1.18 | Beat |
| Aug 14, 2025 | -$0.11 | -$0.09 | Beat |
| May 14, 2025 | -$0.15 | -$0.11 | Beat |